Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / ANO1



This biomarker is also known as:
  • transmembrane protein 16A,
  • Tumor-amplified and overexpressed sequence 2,
  • anoctamin-1,
  • oral cancer overexpressed 2,
  • Transmembrane protein 16A,
  • TAOS2,
  • Discovered on gastrointestinal stromal tumors protein 1,
  • FLJ10261,
  • Oral cancer overexpressed protein 2,
  • ORAOV2,
  • TMEM16A,
  • tumor-amplified and overexpressed sequence 2,
  • DOG1,
  • discovered on gastrointestinal stromal tumors protein 1,
  • transmembrane protein 16A (eight membrane-spanning domains),
  • anoctamin 1, calcium activated chloride channel,

View in BioMuta


ANO1, or anoctamin-1, is a calcium-activated chloride channel gene overexpressed in many tumors. ANO1 is ubiquitously expressed in epithelia and is thought to be important in epithelial fluid transport.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


ANO1 is located within the 11q13 amplicon, one of the most frequently amplified chromosomal regions in human cancer. ANO1 is amplified and highly expressed in breast cancer cell lines and primary tumors.

Performance Comment

ANO1 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.


The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 03/06/2014

Thank you to everyone who helped make the 27th EDRN Steering Committee Meeting a success. We look forward to seeing everyone at the 9th EDRN Scientific Workshop from September 8-11, 2014 in Washington D.C.